EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)ÄquivalenzstudieOpen Access · CC BY-NC 4.0

Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine

Elisa de Lazzari iD, Eugenia B Negredo, Pere Domingo iD, Juan M Tiraboschi iD, Esteve Ribera, Nadia Abdulghani, Verònica Alba, Salvador Fernández-Arroyo, Consuelo Viladés, Joaquim Peraire, Jose M Gatell, Jose L Blanco und 3 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae083 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Elisa de Lazzari und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clinic - IDIBAPS, Barcelona, Spain. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, HIV Infections, Piperazines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondo de Investigacion Sanitaria, European Regional Development Fund, European Social Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The DOLAM trial revealed that switching from triple antiretroviral therapy (three-drug regimen; 3DR) to dolutegravir plus lamivudine (two-drug regimen; 2DR) was virologically non-inferior to continuing 3DR after 48 weeks of follow-up. Weight increased with 2DR relative to 3DR but it did not impact on metabolic parameters.

Methods

Multiomics plasma profile was performed to gain further insight into whether this therapy switch might affect specific biological pathways. DOLAM (EudraCT 201500027435) is a Phase 4, randomized, open-label, non-inferiority trial in which virologically suppressed persons with HIV treated with 3DR were assigned (1:1) to switch to 2DR or to continue 3DR for 48 weeks. Untargeted proteomics, metabolomics and lipidomics analyses were performed at baseline and at 48 weeks. Univariate and multivariate analyses were performed to identify changes in key molecules between both therapy arms.

Results

Switching from 3DR to 2DR showed a multiomic impact on circulating plasma concentration of N-acetylmuramoyl-L-alanine amidase (Q96PD5), insulin-like growth factor-binding protein 3 (A6XND0), alanine and triglyceride (TG) (48:0). Correlation analyses identified an association among the up-regulation of these four molecules in persons treated with 2DR.

Conclusions

Untargeted multiomics profiling studies identified molecular changes potentially associated with inflammation immune pathways, and with lipid and glucose metabolism. Although these changes could be associated with potential metabolic or cardiovascular consequences, their clinical significance remains uncertain. Further work is needed to confirm these findings and to assess their long-term clinical consequences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesHeterocyclic Compounds, 3-RingHIV InfectionsPiperazinesLamivudineOxazinesHumansMaleFemaleAdultMiddle AgedMetabolomicsLipidomicsAnti-HIV AgentsPlasmaProteomicsAntiretroviral Therapy, Highly ActiveDrug SubstitutionTriglyceridesAlanineMultiomicsDolutegravir

Substanzen

PyridonesHeterocyclic Compounds, 3-RingPiperazinesLamivudineOxazinesAnti-HIV AgentsTriglyceridesAlanineDolutegravir

Autor:innen und Institutionen

  • Hospital Clinic - IDIBAPS, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Universitat de Barcelona, Barcelona, Spain.
  • Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Hospital Universitario de Bellvitge, Barcelona, Spain.

ORCID-Profile: Elisa de Lazzari, Pere Domingo, Juan M Tiraboschi, Esteban Martinez

Förderung

  • Fondo de Investigacion Sanitaria
  • European Regional Development Fund
  • European Social Fund
  • IISPV
  • GeSIDA
  • Instituto de Salud Carlos III
  • Hospital Clínic, Barcelona
  • ViiV Healthcare

Zitieren

APA

de Lazzari, E., Negredo, E. B., Domingo, P., Tiraboschi, J. M., Ribera, E., Abdulghani, N., Alba, V., Fernández-Arroyo, S., Viladés, C., Peraire, J., Gatell, J. M., Blanco, J. L., Vidal, F., Rull, A., & Martinez, E. (2024). Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae083

Vancouver

de Lazzari E, Negredo EB, Domingo P, Tiraboschi JM, Ribera E, Abdulghani N, et al. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae083

BibTeX
@article{deLazzari2024,
  author = {de Lazzari, Elisa and Negredo, Eugenia B and Domingo, Pere and Tiraboschi, Juan M and Ribera, Esteve and Abdulghani, Nadia and Alba, Verònica and Fernández-Arroyo, Salvador and Viladés, Consuelo and Peraire, Joaquim and Gatell, Jose M and Blanco, Jose L and Vidal, Francesc and Rull, Anna and Martinez, Esteban},
  title = {Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae083}
}
Kostenlos starten →